Opendata, web and dolomites

PCSP

Odour-GPCRs based technology for detection and stratification of cancer: Prostate Cancer Smell Print as first vertical market

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PCSP project word cloud

Explore the words cloud of the PCSP project. It provides you a very rough idea of what is the project "PCSP" about.

tested    broad    diagnosis    saving    validation    clinical    patented    heterologous    array    recognition    invasive    fluorescent    smell    trial    analysed    discrimination    positives    definition    producing    pca    resembles    antigen    readable    identification    physicians    detect    regulatory    urine    points    nose    gain    print    difficult    signalling    ogpcr    diagnostic    volatile    cells    ogpcrs    clinic    assays    organic    detection    cascade    prostate    expertise    care    biotech    unmet    ed    appropriate    false    universal    pretends    financial    scenarios    acquisition    dogs    prototype    accuracy    canvax    showed    patients    extension    initial    standard    scalable    technology    transferring    anxiety    stress    adoption    born    amount    expression    cover    penetration    screening    coupling    samples    activation    selling    accurate    percentage    quantify    feasibility    cancer    ideal    technologies    expressing    subject    compounds    permits    pcsp    market    unnecessary    types    detecting    negatives    receptors    dog    trained    risky    owns    olfactory    appreciable   

Project "PCSP" data sheet

The following table provides information about the project.

Coordinator
CANVAX BIOTECH SL 

Organization address
address: POLIG TECNOCORDOBA CL 14 E PARC 47 PLANTA 2
city: CORDOBA
postcode: 14014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://canvaxbiotech.com/canvax-is-awarded-with-phase-i-sme-instrument-h2020/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CANVAX BIOTECH SL ES (CORDOBA) coordinator 50˙000.00

Map

 Project objective

PCSP project is born out of the unique expertise developed after years of R&D at Canvax Biotech, and aims at transferring a technology to cover an unmet clinical need, accurate diagnosis of prostate cancer (PCa). Canvax owns a unique set of patented technologies: i) high expression of olfactory receptors (oGPCRs) in heterologous cells, ii) coupling to a signalling cascade and iii) readable fluorescent assays to quantify oGPCR activation. Canvax is producing an array of cells expressing oGPCRs that could be used to detect several types of cancer, including PCa, by detecting cancer-associated volatile organic compounds in urine. The technology is currently being tested in a PCa clinical trial. PCa detection has been widely carried out using the prostate specific antigen test. However, its low accuracy resulted in a high percentage of false positives and a still appreciable amount of false negatives. Several recent studies showed that trained dogs could detect PCa from urine samples with the higher accuracy. However, the use of dogs in clinic is difficult and non-scalable. Canvax PCSP test resembles a dog nose that pretends to be a universal screening method for PCa-type discrimination identifying, in simple urine test, patients in need of further, more invasive diagnostic procedures with higher accuracy than current standard of care, saving stress, anxiety and unnecessary risky procedures. The easy use and low cost of this technology makes it ideal for broad adoption. Different scenarios have been described for market penetration and would be subject of the feasibility study during phase I: Smell print definition, regulatory and market permits acquisition, clinical trial design, identification of best-selling points, EU extension and financial costs will be analysed. The appropriate measures will be applied during phase II, together with prototype validation in a large clinical trial to gain recognition within the physicians, and initial exploitation of the technology

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PCSP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PCSP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More